Accessibility Menu
AstraZeneca Plc logo

AstraZeneca Plc(LSE) AZN

Market Cap£183.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1993)+5,300%
5 Year+46%
1 Year+9%
1 Month-16%
£118.96
+0.39%
+0.46Today
AstraZeneca Plc last closing stock price
MetricPriceDate
Last closeGBX 11,896.002026-08-07
AstraZeneca Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.83%GBX 12,632.002026-07-31
1 month-16.46%GBX 14,240.002026-07-08
3 month-10.85%GBX 13,344.002026-05-08
Year to date-13.73%GBX 13,790.002025-12-31
1 year+8.64%GBX 10,950.002025-08-07
3 year+7.85%GBX 11,030.002023-08-08
5 year+45.84%GBX 8,157.002021-08-06
Since inception+5,300.02%GBX 2.191993-05-12

AstraZeneca Plc Financials at a Glance

Market Cap

£183.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$61.27B

Net Income (TTM)

$10.43B

EPS (TTM)

£4.98

P/E Ratio

23.61

Dividend

£3.16

Beta (Volatility)

0.05 (Low)

Price

£118.96

Volume

12,677,926

Open

£118.98

Previous Close

£118.96

Daily Range

£118.54 - £120.96

52-Week Range

£107.84 - £157.30

Estimated Earnings Date

Oct 30, 2026

AZN News

Digital world map with rising stock trend

How to Invest in Vanguard Total International Stock ETF (VXUS)

Tony DongMay 13, 2026
GettyImages-1166057429

Why Is Everybody Talking About Novavax Stock?

Taylor CarmichaelDec 30, 2020
GettyImages-1211115025

Better Coronavirus Stock: AstraZeneca or Johnson & Johnson

Jason HawthorneOct 17, 2020
GettyImages-624511076

3 High-Yield Stocks at Rock-Bottom Prices

Keith NoonanSep 22, 2018

AstraZeneca Hits Estimates, But GAAP Results Lag Last Year's

Seth JaysonAug 1, 2013

Coming Soon: AstraZeneca Earnings

Seth JaysonJul 29, 2013

Will AstraZeneca Whiff on Revenues Next Quarter?

Seth JaysonJul 23, 2013

10 Shares to Avoid Market Madness

David O’HaraJun 24, 2013
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AstraZeneca Plc

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas, including oncology, cardiovascular, renal, metabolism, respiratory, and rare diseases.

Products and Services
  • Oncology treatments like Calquence, Imfinzi, and Lynparza
  • Cardiovascular and metabolic drugs such as Brilinta and Farxiga
  • Respiratory medications including Symbicort and Fasenra
Growth Outlook
  • Revenue of $15.29 billion in Q1 2026, showing strong demand
  • Trailing twelve months (TTM) net income margin of 17.2%, indicating profitability
  • Strategic partnerships enhancing research capabilities and market reach
Financial Highlights
  • TTM revenue of $60.5 billion, reflecting consistent growth
  • Dividend yield of 1.91%, appealing for income-focused investors
  • Operating income of $4.25 billion in Q1 2026, showcasing operational efficiency
AstraZeneca PLC has established itself as a leader in the biopharmaceutical industry, with a diverse product portfolio that addresses critical health needs globally. The company's focus on innovation and strategic partnerships positions it well for future growth. Recent financial performance indicates strong revenue generation and profitability, making it an attractive option for potential investors. The commitment to research and development continues to drive advancements in treatment options, further solidifying AstraZeneca's role in the healthcare sector.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

96,100

CEO

Pascal Soriot, MBA, DVM

Website

www.astrazeneca.com

Headquarters

Cambridge, CA CB2 0AA, GB

AZN Financials

Key Financial Metrics (TTM)

Gross Margin

79.27%

Operating Margin

22.69%

Net Income Margin

17.02%

Return on Equity

21.68%

Return on Capital

17.55%

Return on Assets

8.96%

Earnings Yield

4.24%

Dividend Yield

2.66%

Payout Ratio

47.05%

Stock Overview

Market Cap

£183.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.55B

Volume

12.68M

Avg. Volume

2.72M

Financials (TTM)

Gross Profit

$48.57B

Operating Income

$13.90B

EBITDA

$20.45B

Operating Cash Flow

$13.74B

Capital Expenditure

-$5.31B

Free Cash Flow

$8.43B

Cash & ST Invst.

$4.99B

Total Debt

$32.41B

AstraZeneca Plc Performance Analysis

AstraZeneca Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 36,005,612,61930.9%
20232023-12-31USD 36,853,651,9952.4%
20242024-12-31USD 42,316,856,34614.8%
20252025-12-31USD 44,570,478,8515.3%
AstraZeneca Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-302.3%
Q42025-12-312.1%
Q12026-03-31-1.4%
Q22026-06-300.0%
AstraZeneca Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.712896.7%
20232023-12-31USD 3.0779.2%
20242024-12-31USD 3.5214.8%
20252025-12-31USD 4.9741.0%
AstraZeneca Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.6%
Q42025-12-31-8.0%
Q12026-03-3132.2%
Q22026-06-30-18.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$15.29B

+3.0%

Gross Profit

$11.25B

+0.8%

Gross Margin

73.55%

N/A

Market Cap

£183.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£1.91M

N/A

Employees

96,100

N/A

Net Income

$2.49B

-0.9%

EBITDA

$5.01B

-1.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.99B

-29.8%

Total Debt

$32.41B

-1.3%

Accounts Receivable

$16.07B

+5.9%

Inventory

$6.97B

+7.7%

Long Term Debt

$26.14B

+0.6%

Short Term Debt

$6.27B

-8.6%

Return on Assets

8.96%

N/A

Return on Invested Capital

16.41%

N/A

Free Cash Flow

$2.15B

+46.8%

Operating Cash Flow

$2.91B

-14.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GSK.LGSK plc
£19.61+1.24%
HLN.LHaleon plc
£3.69-0.32%
SN.LSmith & Nephew plc
£11.13+1.37%
CTEC.LConvaTec Group Plc
£2.32+2.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$128.30+0.12%
TTDThe Trade Desk
$13.85-0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.04+0.05%
NVDANvidia
$221.83+0.01%

Questions About AZN

What is the current price of AstraZeneca Plc?

AstraZeneca Plc is trading at £118.96 per share.

What is the 52-week range for AstraZeneca Plc?

Over the past 52 weeks, AstraZeneca Plc has traded between £107.84 and £157.30.

How much debt does AstraZeneca Plc have?

As of the most recent reporting period, AstraZeneca Plc reported total debt of $24.29B.

How much cash does AstraZeneca Plc have on hand?

AstraZeneca Plc reported $3.69B in cash and cash equivalents in its most recent financial results.

What is AstraZeneca Plc’s dividend yield?

AstraZeneca Plc currently has a dividend yield of 2.66%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services